A phase II, randomized, controlled, observer-blind study to assess the safety, reactogenicity and immunogenicity of two formulations of GlaxoSmithKline (GSK) Biologicals’ Streptococcus pneumoniae prot...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-019730-27

A phase II, randomized, controlled, observer-blind study to assess the safety, reactogenicity and immunogenicity of two formulations of GlaxoSmithKline (GSK) Biologicals’ Streptococcus pneumoniae protein containing vaccine given as a 3-dose primary vaccination course co-administered with DTPa-HBV-IPV/Hib vaccine during the first 6 months of life and as a booster dose at 12-15 months of age

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

First primary objective: Non-inferiority of the candidate pneumococcal vaccine (dPly 10µg and PhtD 10µg) versus 10Pn-PD-DiT vaccine when administered with DTPa-HBV-IPV/Hib as a 3-dose primary vaccination, in terms of post-primary immunization fever > 40.0°C (rectal temperature) with causal relationship to vaccination. Second primary objective (sequential): Non-inferiority of the candidate pneumococcal vaccine (dPly 30µg and PhtD 30µg) versus 10Pn-PD-DiT vaccine when administered with DTPa-HBV-IPV/Hib as a 3-dose primary vaccination, in terms of post-primary immunization fever > 40.0°C (rectal temperature) with causal relationship to vaccination. (see protocol for detailed criteria for non-inferiority)


Critère d'inclusion

  • Three-dose primary vaccination against Streptococcus pneumoniae (S pneumoniae) and Haemophilus influenzae (H influenzae) in healthy infants between 6-14 weeks (42-104 days) of age at the time of the first vaccination and 12-15 months of age at the time of booster vaccination